: iStockAnalyst.com Symbols Feed

BioMed News Bytes: Cytori (NASDAQ: CYTX), Questcor (NASDAQ: QCOR)

Fri, 16 Oct 2009 05:36:14 GMT

Cytori Therapeutics (NASDAQ: CYTX) sent out an email alert to investors on 10/15/09 in the evening pertaining to results that were presented at the 7th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) that demonstrated the safety and feasibility of using a patient’s own adipose-derived stem and regenerative cells (ADRCs) processed by Cytori’s Celution 800 System to treat stress urinary incontinence (SUI)[More...]

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Wed, 07 Oct 2009 19:22:50 GMT

The procedure has been called "one of the most barbaric mistakes ever perpetrated by mainstream medicine." Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.[More...]

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Thu, 24 Sep 2009 23:01:08 GMT

On 4/28/09, Dendreon (NASDAQ: DNDN) announced that its experimental cancer vaccine Provenge extended the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option, Taxotere.[More...]

FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM

Fri, 29 May 2009 12:08:55 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

Cytori Therapeutics: Stock Profile and 2009 Outlook

Sun, 15 Mar 2009 20:13:00 GMT

Cytori Therapeutics (CYTX) is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.[More...]

Stem Cell Index Soars on Lift of Funding Ban

Tue, 10 Mar 2009 01:50:00 GMT

The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 14.2% at a value of 3,387[More...]

Global Stem Cell and Regenerative Medicine Index

Wed, 18 Feb 2009 00:55:00 GMT

The accompanying table (click to enlarge) includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously. The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close[More...]

Stem Cell Index Down 1% in Past Week

Mon, 09 Feb 2009 16:22:00 GMT

The accompanying table (click to enlarge) includes 29 companies in the ETF Innovators (ETFI) Emerging Stem Cell Index, which lost about 1% of market value in the past week and posted an 8.5% loss over the past year on an equal-weight basis. Results for benchmark indexes and ETFs include gains of 1.5% for SPDR S&P Biotech (XBI) and 1.2% for the ETFI Cosmetic and Reconstructive[More...]

Index to Track New Era for Stem Cell Cos.

Fri, 23 Jan 2009 16:12:00 GMT

Shares of Geron (GERN) are soaring today by more than 40% on FDA approval to begin human clinical testing this summer for an embryonic stem cell treatment for spinal cord injuries. The approval comes just days after the new administration took office, breathing new life into related companies such as StemCells (STEM), Aastrom Biosciences (ASTM), and others tracked in the ETF Innovators Cosmetic & Reconstructive Medicine Index. This index and new ETF idea represents a[More...]

Cytori to Raise $4.2 Million in Private Placement

Fri, 08 May 2009 13:50:00 GMT

Cytori Therapeutics, a US-based developer of regenerative medicine, has entered into definitive agreements to raise approximately $4.2 million through a private placement with select investors.
At closing, Cytori will issue and sell to investors 1.86 million units at a purchase price of $2.28 per unit.
Each unit consists of one unregistered share of the company's common stock and 1.75 warrants.

[More...]

Cytori Obtains Patent for Celution System

Wed, 11 Mar 2009 12:13:48 GMT

California-based medical technologies developer Cytori Therapeutics has obtained U.S. Patent No. 7,501,115, which covers methods of cooling and cryopreserving stem and regenerative cells processed by the Celution System.[More...]

Cytori to Raise $10 Million in Direct Offering

Tue, 10 Mar 2009 13:45:24 GMT

California-based pharmaceutical company Cytori Therapeutics has entered into definitive agreements to raise $10 million, before placement agent fees and offering expenses.[More...]

Cytori Reports $30 Million loss

Fri, 06 Mar 2009 12:16:11 GMT

Cytori Therapeutics has reported net loss of $30 million, or $1.12 per share on a basic and diluted basis for 2008, compared to $28.7 million, or $1.25 per share on a basic and diluted basis for 2007.[More...]

StockPreacher.com Issues Trading Outlook for Advanced Cell Technology Inc.

Mon, 24 Aug 2009 10:46:00 GMT

StockPreacher.com announces an investment report featuring stem cell company Advanced Cell Technology Inc. . The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.[More...]

Cytori Reports 2nd Quarter 2009 Financial Results

Mon, 10 Aug 2009 11:46:00 GMT

Cytori Therapeutics (NASDAQ:CYTX) reports financial results for the quarter ended June 30, 2009.
Gross profit was $0.5 million and $1.3 million for the three and six months ended June 30, 2009, respectively, compared to $0.7 million and $0.8 million for the same periods in 2008.
Total operating expenses, less the change in fair value of warrants and option liabilities, were $6.7 million and $13.9 million for the three and six months ended June 30, 2009, respectively, compared to $9.3 million and $18.3 million, for the same respective periods in 2008.

[More...]

Cytori Therapeutics 2nd Quarter Financial Results Conference Call & Shareholder Letter

Fri, 07 Aug 2009 20:40:00 GMT

Cytori Therapeutics (NASDAQ: CYTX) would like to remind investors of its second quarter financial results conference call on Monday, August 10, 2009 at 10:30 AM Eastern Time, during which time the management will host a question and answer session.[More...]

Cytori Therapeutics to Webcast Second Quarter Financial Results on August 10, 2009

Mon, 27 Jul 2009 11:00:00 GMT

Cytori Therapeutics Inc. (NASDAQ: CYTX) will webcast its second quarter financial results and management discussion on Monday, August 10, 2009 at 10:30 AM Eastern Time.[More...]

Cytori Comments on Patent Appeal

Fri, 24 Jul 2009 13:49:00 GMT

Cytori Therapeutics (NASDAQ:CYTX) has been informed that the United States Federal Court in the Central District of California upheld a June 2008 decision relating to U.S. patent number 6,777,231 (the ˜231 patent).
The Court's decision has no impact on Cytori's products or clinical applications under development.
Cytori's products do not practice the '231 patent.

[More...]

Cytori’s Celution® 700 System to be Regulated as a Medical Device by U.S. FDA

Fri, 17 Jul 2009 10:59:00 GMT

Cytori Therapeutics (NASDAQ:CYTX) was informed by the U.S. Food and Drug Administration (FDA) that the Celution® 700 System will be regulated as a medical device under the Federal Food, Drug, and Cosmetic Act. This determination, in response to Cytori’s Request for Designation, clears the way for Cytori to compile and submit a marketing application to the FDA for the Celution® 700 System for use as a medical device in aesthetic body contouring and/or filling of soft tissue voids.[More...]

Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference

Mon, 13 Jul 2009 12:26:00 GMT

Jesup & Lamont, Inc., , a full-service boutique brokerage and investment banking firm serving retail and institutional clients, today announced the LifeTech Capital Group companies presenting at its 2009 Growth Stock & National Sales Conference to be held at the Waldorf Astoria Boca Beach Club on July 30th, 2009 in Boca Raton, Florida. In addition, former FDA Commissioner Dr. Lester M. Crawford D.V.M., Ph.D., will be the keynote speaker for the event.[More...]

Cytori Expands Patent Protection for the Celution® System and Uses for Adipose Derived Stem and Regenerative Cells

Mon, 13 Jul 2009 11:47:00 GMT

Cytori Therapeutics, Inc. (NASDAQ: CYTX) recently received a Notice of Allowance from the U.S. Patent and Trademark Office related to uses of the Celution® System for the treatment of bone related disorders.
Key patent claims cover multiple reagents and additives that are critical for optimizing intravascular delivery of the Celution® System output for indications such as cardiovascular disease, liver disease and renal failure.
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position.

[More...]

Cytori Expands Patent Protection for the Celution® System and Uses for Adipose Derived Stem and Regenerative Cells

Mon, 13 Jul 2009 11:01:00 GMT

Cytori Therapeutics, Inc. (NASDAQ: CYTX) recently received a Notice of Allowance from the U.S. Patent and Trademark Office related to uses of the Celution® System for the treatment of bone related disorders. Specifically, the allowed claims cover prosthetic devices that can be seeded with adipose derived stem and regenerative cells for use in bone healing and regeneration.[More...]

InvestorSoup.com Researches: Oracle, Comcast, Cytori, Wal-Mart, Abbot and GT Solar

Wed, 01 Jul 2009 12:15:00 GMT

Investment opinion and research company InvestorSoup.com announces the availability of free, detailed stock alerts on active stocks in today's news. Each stock alert highlights recent news, trading activity, technical analysis and relevant market research you need to know.[More...]